Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients-Reference-Cited by-同舟云学术

Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients

Published:2021-11-18 Issue:12 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Huse Holly K.¹,Lee Mark J.²,Wootton Mandy³,Sharp Susan E.⁴,Traczewski Maria⁵,LiPuma John J.⁶^ORCID,Jorth Peter⁷^ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine, Harbor-UCLA Medical Center, Torrance, California, USA

2. Department of Pathology and Clinical Microbiology Laboratory, Duke University School of Medicine, Durham, North Carolina, USA

3. Specialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital of Wales, Cardiff, United Kingdom

4. Copan Diagnostics, Murrieta, California, USA

5. Clinical Microbiology Institute, Inc., Wilsonville, Oregon, USA

6. Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA

7. Department of Pathology and Laboratory Medicine, Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA

Abstract

The Burkholderia cepacia complex (BCC) is known for causing serious lung infections in people with cystic fibrosis (CF). These infections can require lung transplantation, eligibility for which may be guided by antimicrobial susceptibility testing (AST).

Funder

Cystic Fibrosis Foundation

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01447-21

Reference39 articles.

1. Cystic Fibrosis Foundation Patient Registry. 2020. 2019 Annual data report.

2. Cystic Fibrosis Foundation Patient Registry. 2016. 2015 Annual data report.